These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 9113329

  • 21. Discovery of inhibitors of the 5-lipoxygenase activating protein (flap).
    Young RN, Gillard JW, Hutchinson JH, Léger S, Prasit P.
    J Lipid Mediat; 1993; 6(1-3):233-8. PubMed ID: 8357984
    [No Abstract] [Full Text] [Related]

  • 22. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.
    Ford-Hutchinson AW.
    Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291
    [Abstract] [Full Text] [Related]

  • 23. [Furo(2,3-c)quinolines and furo(3,4-c)quinolones--synthesis and investigation of lipoxygenase inhibition].
    Görlitzer K, Fabian J, Jones PG, Frohberg P, Drutkowski G.
    Pharmazie; 2002 Mar; 57(3):159-68. PubMed ID: 11933842
    [No Abstract] [Full Text] [Related]

  • 24. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
    Hutchinson JH, Charleson S, Evans JF, Falgueyret JP, Hoogsteen K, Jones TR, Kargman S, Macdonald D, McFarlane CS, Nicholson DW.
    J Med Chem; 1995 Oct 27; 38(22):4538-47. PubMed ID: 7473582
    [Abstract] [Full Text] [Related]

  • 25. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.
    Tagari P, Becker A, Brideau C, Frenette R, Sadl V, Thomas E, Vickers P, Ford-Hutchinson A.
    J Pharmacol Exp Ther; 1993 Apr 27; 265(1):416-25. PubMed ID: 8386242
    [Abstract] [Full Text] [Related]

  • 26. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.
    Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ.
    Life Sci; 1994 Apr 27; 54(9):PL137-42. PubMed ID: 8114608
    [Abstract] [Full Text] [Related]

  • 27. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
    Tagari P, Brideau C, Chan C, Frenette R, Black C, Ford-Hutchinson A.
    Agents Actions; 1993 Sep 27; 40(1-2):62-71. PubMed ID: 8147271
    [Abstract] [Full Text] [Related]

  • 28. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
    Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW.
    Science; 2007 Jul 27; 317(5837):510-2. PubMed ID: 17600184
    [Abstract] [Full Text] [Related]

  • 29. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
    Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF.
    Mol Pharmacol; 1992 May 27; 41(5):873-9. PubMed ID: 1588922
    [Abstract] [Full Text] [Related]

  • 30. Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
    Peduto A, Bruno F, Dehm F, Krauth V, de Caprariis P, Weinigel C, Barz D, Massa A, De Rosa M, Werz O, Filosa R.
    Eur J Med Chem; 2014 Jun 23; 81():492-8. PubMed ID: 24871899
    [Abstract] [Full Text] [Related]

  • 31. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
    Karg EM, Luderer S, Pergola C, Bühring U, Rossi A, Northoff H, Sautebin L, Troschütz R, Werz O.
    J Med Chem; 2009 Jun 11; 52(11):3474-83. PubMed ID: 19492852
    [Abstract] [Full Text] [Related]

  • 32. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
    Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depré M, Hilliard D, Bel EH, Sterk PJ.
    J Allergy Clin Immunol; 1995 Jan 11; 95(1 Pt 1):42-51. PubMed ID: 7822663
    [Abstract] [Full Text] [Related]

  • 33. Chemistry and structure--activity relationships of leukotriene receptor antagonists.
    Bernstein PR.
    Am J Respir Crit Care Med; 1998 Jun 11; 157(6 Pt 2):S220-5; discussion S225-6, S247-8. PubMed ID: 9647603
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4).
    Surette ME, Krump E, Picard S, Borgeat P.
    Mol Pharmacol; 1999 Nov 11; 56(5):1055-62. PubMed ID: 10531413
    [Abstract] [Full Text] [Related]

  • 36. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
    Fang WF, Douglas IS, Wang CC, Kao HC, Chang YT, Tseng CC, Huang KT, Chang HC, Lin MC.
    PLoS One; 2014 Nov 11; 9(7):e102622. PubMed ID: 25025775
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
    Bäck M.
    Curr Pharm Des; 2009 Nov 11; 15(27):3116-32. PubMed ID: 19754386
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
    Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R.
    Eur J Pharmacol; 1994 Jun 02; 258(1-2):95-102. PubMed ID: 7925604
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.